Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae
PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects
Glasgow, UK, 20 November 2024: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy), one of the UK’s largest public-private…
Cambridge, UK – November 15, 2024 – Stilla Technologies, a global leader in digital PCR (dPCR) solutions, has announced a strategic partnership with Source BioScience, a leading UK-based genomics service provider. This collaboration will bring cutting-edge dPCR technology to the forefront of molecular genetics in the UK and Ireland, with Source BioScience becoming the first provider in the region to offer Stilla’s NIO system.
The partnership will leverage Source BioScience’s infrastructure and expertise in molecular genetics and advanced applications in Next-Generation Sequencing (NGS). The…
A fantastic result for the Cushman & Wakefield EMEA Research and Insight team, taking the top spots at The Ian Cullen Research Prize at the Society of Property Researchers Annual Dinner.
The prize is for presentation of new data, innovative analysis and new ways of thinking.
The shortlist for the Open prize whittled down to just two papers – both by Cushman & Wakefield – Kiran Patel’s Locating Science and Sally Bruer’s European City Logistics.
The final selection for best research paper was awarded to Kiran Patel for Locating Science.
Locating Science is a data-led methodology for…
· EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies · Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection· Data presented at AASLD Liver Meeting, held 15-19 November 2024, San Diego, CA
Cambridge, UK, and Boston, MA, USA, 18 November 2024: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to…
Green AI patents see sharp uptick as EU regulations fuel innovation in sustainable energy
Whilst overall AI patent filings have slowed, green AI patent publications grew 35% in 2023
European applicants dominate green AI, filing almost 50% more patents than US counterparts
London, 6 November 2024: Recognition of the transformational capability of AI in strengthening resilience to climate change and supporting the reduction of emissions has potential to propel the energy sector towards new innovations, according to intellectual property firm Marks & Clerk.
Findings from its latest AI…
We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst. As part of our series of diversity and inclusion events this year, which have included International Women’s Day and PRIDE, we hosted talks, a Q&A and a wellbeing workshop to promote gender inclusivity, equality and allyship at SBC.
The official theme for International Men’s Day 2024, which is recognised on 19 November, is positive male role models. With this in mind, we invited four successful men from the Stevenage Campus to speak about their career journeys, but also share how…
Domainex is the first CRO to have installed the eProtein Discovery system
Installation of Nuclera’s technology expands Domainex’s protein production services
Cambridge, UK, 04 November 2024: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, and Domainex, a multi-award winning provider of integrated, pre-clinical drug discovery services, today announced that Domainex is the first contract research organization (CRO) to have installed the eProtein Discovery system and offer protein production services…
CancerSeq™ FFPE tissues from AMSBIO are pre-screened tumor tissue samples for single nucleotide polymorphisms (SNP’s), insertions and deletions plus copy number variations (CNVs) using targeted Next Generation Sequencing to identify key mutations and mutational hotspots.
A major focus of cancer research is gaining insights into the complex mechanisms driving tumor development. While traditional cancer cell lines or genetically altered cell lines are commonly used as in vitro tumor models, they do not capture the diverse genetic variances present in real tumor tissues, which carry…
Cambridge, UK – 13 November 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial is due to recruit up to 30 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial data readouts are expected by the end of 2025.
Ulcerative colitis, an inflammatory bowel disease, is a debilitating…
06 November 2024 - Partnerships and alliances with external organisations have always been a vital route to growth for healthcare and life sciences, but unfortunately, they don’t always meet their aspirations and objectives. Business transformation expert, Mohi Khan, highlights the key principles for a successful partnership or collaborative relationship to deliver value.
Alliances and partnership spectrum
The healthcare and life sciences sector employs a wide spectrum of partnership arrangements and models. These range from simple, contractual arrangements to mergers and…